Drug intelligence / Profile preview

AAV9-NC-shRNA

Development stage
Preclinical
Lead developer
Sun Yat-sen University
Modality
Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies
Administration
Intravenous
01

Overview

AAV9-NC-shRNA is a research-grade viral vector used as a negative control in gene silencing experiments. It consists of an adeno-associated virus serotype 9 (AAV9) capsid packaging a short hairpin RNA (shRNA) sequence that does not target any known gene (a non-coding or "scramble" sequence). This construct allows researchers to control for the potential biological effects of the AAV9 vector itself and the cellular machinery involved in shRNA processing, rather than the specific knockdown of a target gene. In the context of the provided research, it was used as a comparator for AAV9 vectors targeting the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP1R) to study their roles in intestinal fibrosis and metabolic regulation in Crohn's disease models.

Other names
AAV9-negative control-shRNAAAV-9-negative control-shRNAAAV 9-negative control-shRNAAAV9-scramble-shRNAAAV-9-scramble-shRNAAAV 9-scramble-shRNA

Beyond the preview

Go deeper on AAV9-NC-shRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on AAV9-NC-shRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call